| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CAMBRIDGE, U.K. & LONDON—In a new U.K. partnership, Kymab Limited and Heptares Therapeutics, the wholly owned subsidiary of Sosei Group Corporation, have announced a strategic collaboration for the discovery, development and commercialization of novel antibody therapeutics targeting multiple G protein-coupled receptors (GPCRs). The initial focus for this collaboration will be the field of immuno-oncology.
 
Cells of the innate and adaptive immune system widely express GPCRs, which play significant roles in modulating cell migration and recruitment to the tumor environment, activation, survival, proliferation and differentiation.
 
“GPCRs have long been intractable targets for antibody discovery, resulting in a dearth of products. We believe that our proven StaR technology can unlock this substantial opportunity, not just in immuno-oncology, but also across other therapeutic areas where GPCR-targeted biologics could have a significant impact. By entering into strategic collaborations with companies with world-leading antibody discovery technologies, such as Kymab, we have the potential to discover, develop and commercialize a highly valuable pipeline of new biologic products,” Malcolm Weir, chairman and CEO of Heptares, remarked in a statement regarding the partnership.
 
Per the terms of the agreement, Heptares will leverage its StaR platform for the creation of stable antigens based on multiple GPCR targets selected by the two companies, after which Kymab will apply its Kymouse human antibody discovery platform to generate antibodies in response to immunization with the antigens. Any leads will be progressed by Kymab and Heptares to the clinic. Though no specific financial details were disclosed, the agreement stipulates that the two companies will share the costs of each antibody discovery and development program.
 
“Antibodies are important therapeutic agents for cancer and other indications,” David Chiswell, CEO of Kymab, said in a press release. “Our collaboration with Heptares will allow us to combine stable antigens based on multiple GPCR targets with our world-class Kymouse platform, which has unparalleled diversity and will therefore rapidly identify and yield highly selective potent human monoclonal antibodies for unmet medical needs.”
 
This is the second cancer-based deal Kymab has announced so far this year. In January, the company announced a strategic cancer drug discovery and development alliance with the University of Texas MD Anderson Cancer Center, specifically MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation. The organizations will focus on the development of novel monoclonal antibodies for various cancer types as well as the identification of biomarkers. The alliance is slated for an initial run of five years.
 
Just over a week before the collaboration with Kymab, Heptares also shared news of an agreement in neurology, saying that it had begun a definitive agreement with Allergan Pharmaceuticals International Ltd., the wholly owned subsidiary of Allergan plc, under which Allergan licensed exclusive global rights to a portfolio of novel subtype-selective muscarinic receptor agonists under development for the treatment of major neurological disorders, including Alzheimer’s disease.
 
Heptares will receive $125 million in an upfront payment, and is eligible to receive up to $665 million in contingent milestone payments tied to successful Phase 1, 2 and 3 clinical development and launch of the first three licensed compounds for multiple indications. Heptares could also receive up to roughly $2.5 billion if certain annual sales thresholds are met in the years following product launch, as well as up to double-digit tiered royalties on net sales of products that result from the agreement.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue